Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Cutaneous melanoma is an aggressive skin cancer.
• Identifying prognostic markers for melanoma metastasis is crucial for patient management.
• The transforming growth factor beta (TGF-β) pathway plays a role in cancer progression.

Purpose of the Study:

• To investigate phospho-Smad2 as a prognostic marker in primary cutaneous melanoma.
• To assess the correlation between phospho-Smad2 expression and clinical parameters.
• To understand the role of TGF-β signaling in melanoma development.

Main Methods:

• Analysis of phospho-Smad2 expression in 60 primary cutaneous melanoma tissues (Breslow >1 mm).
• Immunohistochemical assessment of phospho-Smad2 positivity.
• Correlation analysis with clinical parameters: Breslow index, melanoma type, survival, metastasis, sentinel lymph node status, and age.

Main Results:

• Phospho-Smad2 positivity did not correlate with survival or metastasis development.
• Phospho-Smad2 positivity was inversely correlated with tumor thickness (Breslow index).
• Interrelation of phospho-Smad2 phosphorylation in melanoma cells and keratinocytes suggests microenvironmental influence.

Conclusions:

• Phospho-Smad2 is unlikely to be a useful prognostic marker for melanoma metastasis.
• Decreased TGF-β signaling, indicated by reduced Smad2 phosphorylation, may occur in thicker melanomas.
• Local microenvironmental factors likely influence Smad2 phosphorylation in primary melanomas.